TCF-001 TRACK is a decentralized, patient advocacy initiated rare cancer precision medicine clinical trial, NCT04504604.

TRACK provides participating rare cancer patients and their physicians with personalized, actionable genomic information to potentially inform treatment, as well as recommendations for treatments (including clinical trials) from an expert panel of rare cancer clinicians and scientists. Simultaneously, TRACK generates critical genomic data to drive a better understanding of often overlooked rare cancers.

TRACK is currently open to enrollment for:

- Patients with any rare cancer (defined as a solid tumor or lymphoma occurring in less than 6 per 100,000 people per year in the US).
- Patients with cancer of unknown primary.

How TRACK Works:

Qualifying patients can enroll in TRACK from their home using a remote consenting system, allowing full participation with no requirement to travel or change their treating physician.

Patients enrolled in TRACK receive comprehensive genomic profiling (FoundationOne® CDx and FoundationOne® Liquid CDx) at no cost.

The TRACK Virtual Molecular Tumor Board, composed of field-leading rare cancer experts, convenes to review the resulting reports and other data, and provides treatment recommendations to the patient and their treating physician.

Over the year that follows, the TCF study team collects updated study-related medical information from each patient. In addition, comprehensive genomic profiling of blood is repeated multiple times to identify new alterations which could potentially drive additional treatment recommendations.

To learn more about TRACK and how to enroll, visit www.targetcancerfoundation.org/track, or call 617-299-0389.